Grant Number: 5R18FD005957-02 REVISED
FAIN: R18FD005957

Principal Investigator:
Eric Hueste

Project Title: Food Protection Task Force meetings to foster communication, cooperation and collaboration within the State

Mr. Fischer, Bret
Director, Division of Administration
920 Wildwood Drive
Jefferson City, MO 651020570

Award e-mailed to: grants@health.mo.gov

Budget Period: 07/01/2017 – 06/30/2019
Project Period: 09/05/2016 – 06/30/2019

Dear Business Official:

The Food and Drug Administration hereby revises this award (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to MISSOURI STATE DEPT/HEALTH & SENIOR SRV in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

If you have any questions about this award, please contact the Grants Management Specialist and the Project Officer listed in the terms and conditions.

Sincerely yours,

Kimberly Pendleton
Grants Management Officer
Office of Acquisitions & Grants Services
Division of Acquisition Support and Grants
Grants & Assistance Team
FOOD AND DRUG ADMINISTRATION

See additional information below
SECTION I – AWARD DATA – 5R18FD005957-02 REVISED

Award Calculation (U.S. Dollars)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal Direct Costs</td>
<td>$8,866</td>
</tr>
<tr>
<td>Federal F&amp;A Costs</td>
<td>$1,134</td>
</tr>
<tr>
<td>Approved Budget</td>
<td>$10,000</td>
</tr>
<tr>
<td>Federal Share</td>
<td>$10,000</td>
</tr>
<tr>
<td>TOTAL FEDERAL AWARD AMOUNT</td>
<td>$10,000</td>
</tr>
<tr>
<td>AMOUNT OF THIS ACTION (FEDERAL SHARE)</td>
<td>$0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUMMARY TOTALS FOR ALL YEARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>YR</td>
</tr>
<tr>
<td>----</td>
</tr>
<tr>
<td>2</td>
</tr>
</tbody>
</table>

* Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

Fiscal Information:

<table>
<thead>
<tr>
<th>CFDA Number:</th>
<th>93.103</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIN:</td>
<td></td>
</tr>
<tr>
<td>Document Number:</td>
<td>RFD005957A</td>
</tr>
<tr>
<td>PMS AccountType:</td>
<td>P(Subaccount)</td>
</tr>
<tr>
<td>Fiscal Year:</td>
<td>2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IC</th>
<th>CAN</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>FD</td>
<td>6990928</td>
<td>$10,000</td>
</tr>
</tbody>
</table>

* Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

FDA Administrative Data:

| PCC: | ORA02 / OC: 4141 / Processed: FDAKPU 09/12/2018 |

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R18FD005957-02 REVISED

Grant payments will be made available through the DHHS Payment Management System (PMS). PMS is administered by the Division of Payment Management, Program Support Center (PSC), DHHS, Office of the Deputy Assistant Secretary, Finance. Requests for downloadable forms and inquiries regarding payment should be directed to:

Regular Mailing Address:
Division of Payment Management
P.O. Box 6021
Rockville, MD 20852
Telephone: (301) 443-1660

Included are the following Links & Instructions for drawing down funds, reporting expenditures, required forms, and the help desk info:


Grant Recipient Information:
Grant Recipient Forms:  
http://www.dpm.psc.gov/grant_recipient/grantee_forms.aspx?explorer.event=true


The ONE-DHHS Help Desk for PMS Support is now available Monday – Friday from 7 a.m. to 9 p.m. EST (except Federal Holidays). Phone (877) 614-5533; Email PMSSupport@psc.gov

SECTION III – TERMS AND CONDITIONS – 5R18FD005957-02 REVISED

This award is based on the application submitted to, and as approved by, FDA on the above-title project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Grant Award.

b. The restrictions on the expenditure of federal funds in appropriations acts to the extent those restrictions are pertinent to the award.

c. 45 CFR Part 75.

d. The HHS Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.

f. A required Federal Financial Report (FFR) SF-425 must be submitted annually. FDA now requires all annual financial expenditure reports to be submitted electronically using the Federal Financial Report (FFR) system located in the eRA Commons. Annual FFRs must be submitted for each budget period no later than 90 days after the end of the calendar quarter in which the budget period ended. The reporting period for an annual FFR will be that of the budget period for the particular grant; however, the actual submission date is based on the calendar quarter. Failure to submit timely reports may affect future funding.

g. Closeout Requirements (when applicable): A Final Program Progress Activity Report, Final Federal Financial Report SF-425, Final Invention Statement HHS-568 (if applicable), Tangible Personal Property Report SF-428, and Statement of Disposition of Equipment (if applicable) must be submitted within 90 days after the expiration date of the project period.

h. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

This award has been assigned the Federal Award Identification Number (FAIN) R18FD005957. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Treatment of Program Income:
Additional Costs

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75.

SECTION IV – FD Special Terms and Condition – 5R18FD005957-02 REVISED

Page-3
09/11/2018: This award is being revised to provide approval of the grantee's no-cost extension as approved by grants management and the Program Official with no additional cost to the Government as requested in accordance with the correspondence of date 9/11/2018.

All FDA grant and cooperative agreement awards include the HHS Grants Policy Statement as part of the NoA.

FDA Responsibilities

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/index.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html, and http://www.hhs.gov/ocr/understanding/disability/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at the information located at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

FDA considers the sharing of research resources developed through FDA-sponsored research an important means to enhance the value and further the advancement of research. When research resources have been developed with FDA funds and the associated research findings published, those findings must be made readily available to the scientific community.

Upon acceptance for publication, scientific researchers must submit the author’s final manuscript of the peer-reviewed scientific publication resulting from research supported in whole or in part with FDA funds to the NIH National Library of Medicine's (NLM) PubMed Central (PMC). FDA defines the author's final manuscript as the final version accepted for journal publication, which includes all modifications from the publishing peer review process. The PMC archive is the designated repository for these manuscripts for use by the public, health care providers, educators, scientists, and FDA. Please see the FDA Public Access Policy.

Additional terms and conditions regarding FDA regulatory and Office Of Regulatory Affairs programmatic requirements may be part of the Notice of Award.

3. Reporting
When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the Notice of Award.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the HHS Grants Policy Statement. Annual FFRs must be submitted for each budget period no later than 90 days after the end of the calendar quarter in which the budget period ended. The reporting period for an annual FFR will be that of the budget period for the particular grant; however, the actual submission date is based on the calendar quarter. Failure to submit timely reports may affect future funding.

A final Progress Report detailing the project activities/outcomes and a final Federal Financial Report (SF-425) are required within 90 days of the expiration date of the project period as noted on the Notice of Grant Award, or when an award is relinquished, when a recipient changes institutions or when an award is terminated.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable FDA grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000.

Annual FFRs must be submitted for each budget period no later than 90 days after the end of the calendar quarter in which the budget period ended. The reporting period for an annual FFR will be that of the budget period for the particular grant; however, the actual submission date is based on the calendar quarter. Failure to submit timely reports may affect future funding.

Section VII. Agency Contacts

Scientific/Research Contact(s)
Thanh Andrews, Project Officer
Food and Drug Administration (FDA)
Office of Regulatory Affairs
Telephone: 202-815-0889
Email: thanh.andrews@fda.hhs.gov

Financial/Grants Management Contact(s)
Kiara Fowler
Office of Acquisitions & Grants Services (OAGS)
Telephone: 240-402-3099
Email: Kiara.Fowler@fda.hhs.gov

Section VIII. Other Information

All awards are subject to the terms and conditions, cost principles, and other considerations described in the HHS Grants Policy Statement.

Authority and Regulations
Awards are made under the authorization of Sections 301 of the Public Health Service Act as amended (42 USC 241) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.

Direct inquiries regarding scientific programmatic issues to the official listed below.

Direct inquiries regarding fiscal and/or administrative matters to the grants management specialist listed below.

All formal correspondence/reports regarding the grant should be signed by an authorized institutional official and the Principal Investigator and should be sent to the attention of the grants management specialist, unless otherwise explicitly directed.

STAFF CONTACTS

Grants Management Specialist: Kiara Fowler
Email: Kiara.Fowler@fda.hhs.gov

Program Official: Thanh Andrews
Email: Thanh.Andrews@fda.hhs.gov

SPREADSHEET SUMMARY